Gilead Sciences buys XinThera to boost oncology and inflammation pipeline
Pharmaceutical Technology
MAY 10, 2023
XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. Gilead Sciences stated that the two programmes have the potential to address a number of indications and to provide development opportunities both alone and along with its wider portfolio.
Let's personalize your content